New Delhi, 18 September (IANS). Pharma sector giant Lupin has announced that the US Food and Drug Administration has approved its new drug application for cancer patients with a capacity of 2.5 mg to 25 mg.
The company stated in an exchange filing that Lenalidomide has received approval for the treatment of adult patients with multiple myeloma (a deadly blood cancer). Especially when it is used with dexamethasone as maintenance therapy after autologous hematopoetic stem cell transplantation.
The Lenalidomide Capsule is a generic version of the Revide Capsule developed by the American multinational company Bristol-Myers Squib Company.
The statement said that this product will be manufactured at Pithampur plant in Madhya Pradesh, Lupine.
Lupine has announced that the company’s generic product will be an affordable option of revalimids.
The company reported that Lenalidomide capsules of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 20 mg and 25 mg (RLD Revolution) are $ 7,511 million in the US.
Lupine is headquartered in Mumbai. It works as a global pharmaceutical company in more than 100 markets. The company focuses on branded and generic formulation, complex generics, biotechnology products and active pharmaceuticals ingredients.
The company has 15 manufacturing sites and seven research centers around the world, with more than 24,000 employees.
Lupine has also recently received approval from the US administration for generic contraceptive tablet Minjoya.
The drug is the generic equivalent of Balkoltra developed by US based avian pharmaceuticals LLC. Minjoya will also be constructed at the plant in Pithampur, Lupine.
Meanwhile, on Thursday, Lupine shares fell by Rs 0.70 or 0.03 percent to Rs 2,030.50 from the last day’s closed price.
The company’s stock has fallen by Rs 5.30 or 0.26 percent in the last five business days. Whereas, in the last one month, the shares of the drug company have registered an increase of Rs 62.30 or 3.17 percent.
-IANS
SKT/
